Upload
anonymous-v5l8nmcsxb
View
216
Download
0
Embed Size (px)
Citation preview
8/18/2019 Imaging in Ovarian Cancer
1/19
Imaging in ovarian cancer
Ovarian cancer affects mainly post-menopausal women but is not uncommon in pre-menopausal women.
•.
The presentation of ovarian cancer is usually delayed,
and therefore early detection of disease is important.
•.
Imaging has an important role in the detection and
characterisation of adnexal masses with the
primaryimaging modality being transvaginal ultrasound.
•.
Cross-sectional imaging is useful to assess the extent ofdisease prior to surgery, for monitoring treatment
response and for detecting recurrence.
Ovarian cancer is the fifth most common cancer affecting women in the UK and is associated with a worse prognosis
than other forms of gynaecological malignancy. There are increasing numbers of women presenting with ovarian
cancer over the age of 65 years. The diagnosis of ovarian cancer is often delayed, owing to the lack of symptoms and
the nonspecific nature of the disease, particularly in the early stages. The prognosis of advanced ovarian cancer is
poor in the later stages, making early detection of malignancy important. On current classification systems, the
staging of ovarian cancer remains surgical but the role of imaging is contributory throughout the management of
ovarian cancer which defines disease burden. The primary imaging modality for detection of ovarian disease is
transvaginal ultrasound, and !T imaging is predominantly used in the staging of ovarian cancer with "#$ being
reserved as a problemsolving techni%ue, especially in younger women where benign disease is more likely. &ewer
modalities such as positron emission tomography !T are increasingly being recognised in ovarian cancer where
recurrent disease can be diagnosed more %uickly with subse%uent treatment. The role of imaging is discussed with
reference to the different imaging modalities available in the assessment of ovarian malignancy.
Ovarian cancer is the second most common gynaecological cancer and is associated with higher mortality rates
compared with other forms of gynaecological malignancy. The incidence of ovarian cancer is appro'imately ()))
cases per year in the UK *+. The ma-ority of cases occur in women aged over 6) years, but appro'imately +) of
cases occur in younger women. #isk factors for ovarian cancer include nulliparity, early menarche, childbirth after /5years, late menopause and hereditary cancer syndromes. Ovarian stimulation drugs may slightly increase the risk of
ovarian cancer *0, but the use of the oral contraceptive pill is thought to be protective.
1atients are usually asymptomatic in the early stages and may present in the late stages with abdominal distension,
shortness of breath, fatigue or bony pain. 2elayed diagnosis means a poorer prognosis with a survival rate of 530)
in 4tage $$$ or $ ovarian cancer compared with appro'imately ) at 4tage $ */. The overall survival rate in ovarian
cancer has gradually increased but has not significantly changed in latestage ovarian cancer, despite developments
http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060
8/18/2019 Imaging in Ovarian Cancer
2/19
in diagnosis and treatment */. 7arly detection re%uires a multidisciplinary approach, with a thorough clinical
assessment combined with appropriate imaging techni%ues and tumour markers.
Investigation4ection8
1atients should initially undergo a pelvic bimanual e'amination, after which serum cancer antigen +05 9!:+05;
levels and a pelvic ultrasound may be performed. !:+05 is a poor marker for screening as only 5) of 4tage $
tumours will elevate !:+05 *
8/18/2019 Imaging in Ovarian Cancer
3/19
Ovarian tumours are graded as well 9+);, moderately 905; and poorly differentiated 965; *+
8/18/2019 Imaging in Ovarian Cancer
4/19
:bout ()3(5 of patients with ovarian cancer have tumour spread beyond the pelvis at the time of diagnosis *0.
4pread in ovarian cancer occurs primarily by intraperitoneal dissemination due to tumour cells shedding into the
peritoneum and being distributed in a clockwise fashion. The commonest sites for spread are the pouch of 2ouglas,
the right subphrenic space and the omentum */). :typical sites include the ligamentum teres, gastrosplenic,
gastrohepatic ligaments and splenic hilum */+. Eocal spread occurs within the pelvis, to the opposite ovary, uterus,fallopian tubes, bladder, rectum and pelvic side wall. &odal metastases spread via the lymphatics to the paraaortic
chain, along the ovarian vessels and via the broad ligament to the internal iliac, obturator and e'ternal iliac nodes.
4pread to superficial and deep inguinal nodes is via the round ligament. 2istant metastases are rare at the time of
diagnosis, but metastatic sites include the liver, spleen, pleura, lung, adrenals and, less commonly, the skeleton and
brain.
4taging remains surgical and is performed in accordance with $nternational Federation of ynecology and Obstetrics
9F$O; staging system 9Table +; */0. 4tage $ refers to tumour confined to the ovaries, 4tage $$ to ovarian cancer with
peritoneal metastases confined to the true pelvis, 4tage $$$ to e'trapelvic peritoneal or abdominopelvic metastases
and 4tage $ to metastases outside the abdomen and pelvis. The surgical procedure aims to stage regions according
to the spread of cancer and involves aspiration of ascites or washings of the pelvis and paracolic gutters. : total
hysterectomy and bilateral oophorectomy is usually performed. Fertility preservation can only be considered in
patients with 4tage $: disease, where dilatation and curettage, unilateral oophorectomy and inspection of
the contralateral ovary are undertaken. :ll organs and peritoneal surfaces are visualised for disease spread. :n
infracolic omentatectomy and biopsies of the pelvic peritoneum, culdesac, bladder reflection, paracolic gutters and
diaphragm are performed *0. :ny suspicious lymph nodes are e'cised, although some authors advocate systematic
e'cision of bilateral obturator, left renal vein and retroperitoneal nodes *//. :ppendectomy is recommended in
suspected mucinous tumours */
8/18/2019 Imaging in Ovarian Cancer
5/19
"tag
e
#ercenta
ge atdiagnosis
$escription
%-year
survivala
Intracapsula
r and
bilateralIC* )ctual
or potential
microscopic peritoneal
contaminati
on
II &%'
II)*Involvemen
t of
fallopian
tubes oruterus
%%'
II+*
Involvement of other
pelvic
tissues e.g.sigmoid
pelvic
implants
IIC* )ctual
or potentialmicroscopic
peritonealcontaminati
on
III &%'
III)*icroscopic
abdominal
implants
'
III+* /& cmabdominal
implants
IIIC* 0& cmabdominal
implants or
positivenodes
I1 &%' $istant '
8/18/2019 Imaging in Ovarian Cancer
6/19
"tag
e
#ercenta
ge atdiagnosis
$escription
%-year
survivala
spread
2e.g.maligna
nt pleuraleffusion,
intrahepatic
metastases3
a4ource8 KurtL :B, Tsimakas, Tempany !"!, Damper U", :rger 1D, Bree #E, et al. 2iagnosis and staging of
ovarian cancer8 comparative values of doppler and conventional U4, !T and "#imagingcorrelated with surgery and
histopathologic analysisMreportof the#adiology 2iagnostic Oncology roup.Radiology +C0+08+30(.
Treatment4ection8
The standard management of ovarian carcinoma is primary debulking surgery 9124; followed by chemotherapy.
4tages $3$$$ are primarily treated with surgical cytoreduction and 4tage $ is managed with chemotherapy. 124 refers
to initial resection of all tumour sites leaving no macroscopic residual disease. $n advanced cases, complete surgical
resection may not be possible and optimal disease reduction with residual sites of less than +30 cm is considered
acceptable */(. 124 should be performed by a trained gynaeoncology surgeon, preferably in a cancer centre */>.
4urgical disease volume reduction facilitates the response to chemotherapeutic agents */ by reduction in tumour
bulk, which responds more effectively and improves overall survival *
8/18/2019 Imaging in Ovarian Cancer
7/19
Ultrasound
The ma-ority of patients with suspected ovarian cancer will undergo a pelvic ultrasound, which includes both
transabdominal and TU4. Transabdominal scans evaluate larger pelvic masses and focused ultrasound with TU4
due to the close pro'imity of the probe allows a more focussed assessment of the ovaries and adne'al masses. The
siLe and morphology of the ovaries and the relationship of any pelvic masses to the ovaries and uterus can be
assessed. The internal composition of a mass can be determined and whether it is predominantly solid or cystic,unilocular or multilocular. The vascularity of solid components and the presence of calcification or internal septae can
be demonstrated well on ultrasound. 4imple follicular cysts, corpus luteal cysts, endometriomas and benign cystic
teratomas can be identified confidently with ultrasound and will obviate the need for furtherimaging 9Figure +;. 4imple
cysts @5 cm are likely to be benign, especially in premenopausal women *
8/18/2019 Imaging in Ovarian Cancer
8/19
Figure 3. : solid mass within the left ovary clearly demonstrating central internal blood flow in a comple' cystic mass withabnormal doppler indices 9pulsatility inde' @+, resist ive inde' @).>3+)) and specificity of 6036 *5>.
Ultrasound has a lower detection rate for peritoneal metastases than !T or "#$ *5 and certain tumours such as
borderline ovarian tumours may be more difficult to assess accurately, although the presence of papillae or multiple
septae is suggestive 9Figure
8/18/2019 Imaging in Ovarian Cancer
9/19
Figure ". 9a; :'ial T + weighted fast spin echo "#$ showing a welldefined comple' pelvic mass containing highsignalmaterial superiorly. 9b; T + weighted fatsuppressed se%uences demonstrate signal dropout in the superior aspect of thismass 9star;, indicating the presence of macroscopic fat, which is consistent with a benign cystic teratoma.
Figure #. : tubulocystic mass in the pouch of 2ouglas is demonstrated well on a'ial and sagittal "#$images. Theappearances are those of a haematosalpin'. The structure is hyperintense on the a'ialT + weighted images and becomes
more conspicuous on fatsuppressed se%uences. &ot the intermediate signal intensity on the sagittal T 0
weighted se%uence.
"#$ is not widely used in ovarian cancer in some centres and may relate to cost issues, lack of availability and the
variability of study %uality. Both !T and "#$ are superior to ultrasound in the assessment of the nature of ovarian
masses, with the highest accuracy for "#$ *66. "#$ is useful in the assessment of local tumour invasion and for
evaluating local spread to the uterus, bladder, rectum or pelvic sidewall. 4imilar to !T, it can be used to detect tumour
residuum or recurrence. 2ue to the lack of ionising radiation, "#$ is indicated in patients who are allergic to iodinated
contrast, pregnant patients and younger women. $t has a higher specificity than ultrasound *66, and is helpful in
characterising lesions where ultrasound and !T e'aminations have been inconclusiveC it is most useful in those with
a low likelihood of malignancy where surgery can be avoided *6(, 6>. $ts multiplanar capability and better soft tissue
characterisation relating to tissue signal characteristics make it more useful than !T or ultrasound in helping to
confirm benign disease 9Figure 6;. Dowever, it is not suitable for all patients, such as those with claustrophobia, a
large body habitus and those with "#$incompatible metallic implants or difficulties with breathholding.
The features that increase the suspicion for malignancy on "#$ are similar to those found on ultrasound with solid
nonfatty, nonfibrous tissue or cysts with thick walls, septations and papillary pro-ections. 1apillary pro-ections are
seen in 0 of malignant tumours *6+. The most predictive features for malignancy are enhancing tissue 9Figure (;,
vegetations in a cystic lesion, a diameter of more than 6 cm and necrosis *6, (). 1elvic organ invasion, implants,
ascites and enlarged lymph nodes increase the likelihood of malignancy. Uterine invasion is identified as distortionof
the uterine contour, an irregular interface between the tumour and the myometrium and increased signal intensityof
the myometrium. Eoss of the fat plane between the solid component of the tumour and the ad-acent bowel
orbladder can indicate local invasion. 1elvic wall invasion can be diagnosed when tumour reaches the sidewall to
within / mm or when iliac vessels are surrounded and distorted *(+.
Figure $. : comple' cystic pelvic mass in a /6yearold woman. The internal septum and the nodule 9arrow; demonstrateenhancement following intravenous gadolinium and is therefore highly suggestive of malignancy.
$n a prospective study of adne'al masses, "#$ showed a sensitivity of +)) and specificity of and peritoneal metastases, but "#$ is more accurate for lymph node metastases *6+, local disease and
liver metastases.
%T4ection8
!hoose
http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060
8/18/2019 Imaging in Ovarian Cancer
10/19
!T is widely available and allows rapid evaluation of the whole abdomen and pelvis. Oral contrast may be helpful to
opacify the small bowel and colon to facilitate the differentiation of adne'al structures from bowel loops and pelvic
structures *(+. 1atients with calcified peritoneal disease may have metastases obscured by positive oral contrast and
therefore re%uire oral water 9Figure >;. 1atients are re%uired to have a full bladder and are usually given + l of dilute
9/; astrografin 9Bracco, "ilan, $taly; at least + h prior to the scan. The use of intravenous contrast helps to
characterise the internal structure of adne'al masses and to make peritoneal disease more conspicuous. $ts mainstay
is in assessing e'traovarian and distant disease, and disease that may be less amenable to surgery. 1articular siteswhere surgical resection may be more difficult are supradiaphragmatic 9Figure ;, subdiaphragmatic recesses 9Figure
+);, liver parenchyma, supracolic omentum, suprarenal lymph nodes and small bowel mesentery 9Figure ++;.
Figure &. :'ial !T section through the lower abdomen showing calcified omental disease in a patient with mucinouscystadenocarcinoma. This is distinguished from ad-acent bowel, which contains a negative oral contrast agent.
Figure '. &umerous paracardiac or cardiophrenic lymph nodes 9arrow; in a patient with 4tage $$$ ovarian cancer.
Figure 1(. &odular thickening of the right hemidiaphragm due to subdiaphragmatic disease. &ote the peritoneal diseasemedial to the spleen 9arrow;.
Figure 11. $lldefined streaky soft tissue opacity in the root of the small bowel mesentery due to peritoneal disease 9arrow;.There is also ascites in the right paracolic gutter.
The specific features of ovarian malignancy on !T are pelvic masses greater than < cm, cystic masses of variable
density, wall irregularity, thick septa 9N/ mm;, vegetations and solid enhancing components within adne'al masses.
1eritoneal disease is highly suggestive of malignancy and is demonstrated as thickening, nodularity and abnormal
enhancement of the peritoneum. !alcified deposits within the peritoneum may be seen in serous cyst
adenocarcinomas *(0. 1eritoneal disease is commonly seen in the paracolic gutter, omentum, bowel serosa 9Figure
+0;, liver surface, subphrenic spaces and mesentery. $t is important to review deposits close to the diaphragm on
coronal reformats 9Figure +/; as deposits ad-acent to the liver can be difficult to discriminate from subcapsular
deposits, which are 4tage $$$ disease, and liver parenchymal involvement, which is 4tage $ disease 9Figures
+
8/18/2019 Imaging in Ovarian Cancer
11/19
Figure 12. 7'tensive thickening and serosal disease of the sigmoid colon 9arrow; with further peritoneal disease seen alongthe right pelvic side wall.
Figure 13. !oronal reformats can help to identify subdiaphragmatic and subcapsular disease more easily. &ote thesubdiaphragmatic disease inferior to the right hemidiaphragm 9arrow;.
Figure 14. There is an invasive subcapsular deposit in the posterior part of the right lobe of liver 9arrow;, which should notbe mistaken for a parenchymal metastasis. 4ignificantly enlarged periportal lymphadenopathy 9star; is also seen in thispatient with 4tage $$$ ovarian cancer.
Figure 1". : parenchymal metastasis in a patient with 4tage $ ovarian cancer. &ote the periportal lymphadenopathy andleft adrenal metastasis.
1elvic ascites, although suggestive of malignancy, is not specific for malignancy, and may be present in ovarian
torsion, pelvic inflammatory disease and benign ovarian fibromas *(
8/18/2019 Imaging in Ovarian Cancer
12/19
and can be used along with other forms of crosssectional imaging such as "#$ and newer modalities such as
positron emission tomography 917T;=!T.
)ositron emission tomography %T4ection8
17T=!T can detect e'trapelvic disease and distant metastases, and is an alternative to !T imaging for the evaluation
of hypermetabolic implants, especially on the subdiaphragmatic, subhepatic, serosal and subcapsular surfaces
9Figure +6;. Fluorodeo'yglucose 9F2; 17T=!T combines metabolic information with the anatomical information
obtained from !T to increase the accuracy of imaging *(>. :lthough 17T=!T can serve as both a primary staging tool
and for evaluating recurrence, its strength lies in detecting recurrence, where it is particularly useful in distinguishing
later stages of ovarian cancer, with an accuracy of 5 *(, >). 4tudies have reported low sensitivities and
specificities for detecting primary ovarian cancer *>+, >0.
Figure 1#. : subcapsular liver deposit is shown as a highly metabolic lesion on coronal positron emissiontomography=!T images 9arrow;. There is also left hydronephrosis.
The usefulness of 17T=!T may be limited in premenopausal women, where high rates of falsepositive results can
occur with benign disease and high falsenegative results with borderline tumours, lowgrade and early
adenocarcinomas *>/. 1hysiological uptake in the pelvis due to superimposed bladder and bowel activity can make
assessment of the pelvis challenging. Benign conditions such as endometriosis, hydrosalpinges, pedunculated
fibroids and benign ovarian tumours are associated with high uptake 9Figure +(; *>; *>5. Ovarian
tracer uptake should therefore be correlated carefully with menstrual status and phase. : study by !astellucci
suggests that a standard uptake value 94U; of / or more is positive for malignancy and a 4U of up to 0.( is
considered benign *>). $ncidental avid ovarian uptake in a postmenopausal woman should be investigated further
with TU4 and correlated with !:+05 as uptake is unlikely to be physiological. :bnormal lymph nodes are better
detected on 17T=!T as conventional imaging relies on siLe criteria to distinguish pathological nodes, but 17T=!T
adds functional information 9Figure +;. !T is traditionally very sensitive for detecting peritoneal implants but small
peritoneal implants less than ( mm may be difficult to identify on 17T=!T. 4tudies report high a sensitivity of >( and
specificity of +)) *>6, although it is not the preferred techni%ue of staging it is comparable in accuracy to !T. $n
addition to !T, it can evaluate e'trapelvic disease and distant metastases more easily demonstrated compared with
!T alone 9Figure 0); *>(. $t has been shown to more significantly influence the management of patients with
suspected disease recurrence where other studies have been negative or inconclusive *>>.
Figure 1$. : fused a'ial positron emission tomography=!T image showing no uptake in a benign cystic teratoma. &ormalbowel uptake is noted around the teratoma.
!hoose
http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060http://www.birpublications.org/doi/full/10.1259/imaging.20100060
8/18/2019 Imaging in Ovarian Cancer
13/19
Figure 1&. 9a; Benign physiological uptake in both ovaries indicated by bilateral faint uptake. 9b; "arked bilateral uptakewithin the ovaries in a patient with ovarian metastases secondary to melanoma.
Figure 1'. 9a; There is a single enlarged aortocaval node shown on !T 9arrows; in a patient with known ovarian cancer. 9b;This node shows avid uptake on positron emission tomography=!T, indicating metastatic involvement. $t was resected andconfirmed to represent recurrent disease.
Figure 2(. 9a; : metastatic lesion in the spleen in a patient with 4tage $ ovarian cancer. 9b; This lesion shows markeduptake on the corresponding positron emission tomography=!T image.
7arly diagnosis of disease relapse is important as up to (5 of patients with ovarian cancer will relapse *>, and
although !:+05 is a sensitive marker for relapse, relevant sites of recurrence need to be identified early 9Figure 0);.
17T=!T performs better than !T or "#$ in the detection of recurrence *), with high sensitivity for disease
recurrence 9sensitivity +, specificity >>; *+. Falsepositives can occur in assessing patients following surgery,with inflammatory change or fibrosis and in tumours less than / weeks post chemotherapy *0. 17T=!T can modify
treatment planning and is an important tool for patients with suspected recurrent disease where !T and "# have
been negative or inconclusive */.
%onclusion4ection8
There are multiple imaging modalities available for the radiologist in assessing ovarian cancer. Ultrasound is useful
as a firstline investigation for suspected malignancy and identifying the need for further imaging. "#$ can
characterise adne'al masses with more accuracy and may prevent surgery in those with benign pathology especially
in younger women. !T and "#$ have a similar accuracy in the assessment of e'trapelvic disease, but the wider
availability and reproducibility of !T makes it more useful in the preoperative setting. Both !T and 17T=!T are
utilised in assessing response to treatment, and detecting disease progression and relapse. 17T=!T is less readily
available and is currently being implemented in specific settings such as detection of recurrence or for clarification of
disease in patients being considered for secondary debulking surgery.
!e*erences4ection8
. Cancer 4esearch 56. Cancer incidence for common cancers. &778 9cited & :ovember &7;.)vailablefrom* http*
8/18/2019 Imaging in Ovarian Cancer
14/19
)vailable from* http*
8/18/2019 Imaging in Ovarian Cancer
15/19
&E
.
Jaino 4H, 5nger A4, Bhitney C. "ynchronous carcinomas of the uterine corpus and
ovary. (ynecol %ncol 8(D8*E&8FE%. Cross4ef
&.
Bu TT, Coa=ley 1, Kayyum ). agnetic resonance imaging of ovarian cancer arising inendometriomas. J Comput A$$i$t "omogr &77D&(*(EGF(. Cross4ef
&%
.
anchul @), "imm H, @evin B. +orderline epithelial ovarian tumours* a review of ( cases
with an assessmentof the impact of treatment. !nt J Radiat %ncol iol Phy$ 88&D&&*(GF . Cross4ef
&G
.
@ee 64, "cully 4A. ucinous tumours of the ovary* a clinicopathologic study of 8G
borderline tumours 2of intestinal type3 and carcinomas, including an evaluation of cases
with Lpseudomyoxoma peritoneiM. Am J Surg Path &777D&*FG. Cross4ef
&
.
Axacoustos A, 4omanini A, 4inaldo $, )moroso C, "abolcs +, Jupi A, et
al.. #reoperative sonographic features of borderline ovarian tumours. 'ltra$ound %b$tet
(ynecol &77%D&%*%7F8. Cross4ef
&(
.
$e"oua :, ON:eill 4, cIndoe !), $ina 4, "outter B#. +orderline tumours of
the ovary* CT and 4I features and tumour mar=ers in differentiation from "tage I
disease. AJR Am J Roentgenol &77%D(*888F77E.Cross4ef
&8.
ader ):, 4ose #!. 4ole of "urgery in Ovarian Carcinoma. J Clin %ncol D&%*&(EF(E.
E7
.
@eblanc A, "onoda , :arducci , erron !, Kuerleu $. @aparoscopic staging of early
ovarian carcinoma. Curr %pin %b$tet (ynecol &77GD(*7F&. Cross4ef
E
.
+uy H:, oss )), !hossain ), "ciot C, albec @, 1adrot $, et al.. #eritoneal implants
from ovarian tumours* CT findings. Radiology 8((DG8*8GF.
E&
.
?eint )#, Odicino , aisonneuve #, Kuinn ), +enedet H@, Creasman BT, et
al.. Carcinoma of the ovary !nt J (ynecol %b$tet &77GD8%"uppl. 3"GE.
EE
.
Cass I, @i )H, 4unowic C$, ields )@, !oldberg !@, @euchter 4", et al.. #attern of lymph
node metastasis in clinically unilateral stage I invasive epithelial ovarian
carcinomas. (ynecol %ncol &77D(7*%GFG. Cross4ef E
.
)yhan ), !ulte=in , Tas=iran C, Cagatay ", ehmut :, uce , et al.. 4outine
appendectomy in epithelial ovarian carcinoma* is it necessaryP %b$tetr
(ynecol &77%D7%*8F&. Cross4ef
E%.
Chan H6, unro A!, Cheung 6, ?usin ), Teng ::, +ere= H", et al.. )ssociation oflymphadenectomy and survival in "tage I ovarian cancer patients. %b$tet
(ynecol &77D78*&F8. Cross4ef
EG.
oung 4C, $ec=er $!, Bharton HT, #ivan ", "indelar B, Adwards +6, et al.. "taginglaparotomy and ovarian cancer. JAMA 8(ED&%7*E7&FG. Cross4ef
E
.
?os=ins BH, c!uire B#, +rady , ?omesley ?$, Creasman BT, +erman , et al.. The
effect of diameter of largest residual disease on survival after primary cytoreductive surgery
in patients with suboptimal residual epithelial ovarian carcinoma. Am J %b$tet(ynecol 88D7*8F(7. Cross4ef
E(
.
6ehoe H, #owell ", Bilson ", Boodman C. The influence of the operating surgeonNs
specialisation on patient survival in ovarian carcinoma. r J of Cancer 88D7*7F . Cross4ef
E8
.
!oldie H?, Coldman H). ) mathematic model for relating the drug sensitivity of tumors to
their spontaneous mutation rate. Cancer "reat Rep 88DGE*&FEE.
7 +ertelson 6. Tumor reduction surgery and long-term survival in advanced ovarian cancer* a
http://www.birpublications.org/servlet/linkout?suffix=b23&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0090-8258(84)90200-2http://www.birpublications.org/servlet/linkout?suffix=b24&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F00004728-200411000-00018http://www.birpublications.org/servlet/linkout?suffix=b25&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0360-3016(92)90781-Chttp://www.birpublications.org/servlet/linkout?suffix=b25&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0360-3016(92)90781-Chttp://www.birpublications.org/servlet/linkout?suffix=b26&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F00000478-200011000-00001http://www.birpublications.org/servlet/linkout?suffix=b27&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1002%2Fuog.1823http://www.birpublications.org/servlet/linkout?suffix=b28&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.184.3.01840999http://www.birpublications.org/servlet/linkout?suffix=b28&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.184.3.01840999http://www.birpublications.org/servlet/linkout?suffix=b30&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F01.gco.0000233935.51801.48http://www.birpublications.org/servlet/linkout?suffix=b33&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1006%2Fgyno.2000.6027http://www.birpublications.org/servlet/linkout?suffix=b34&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F01.AOG.0000154884.20872.c4http://www.birpublications.org/servlet/linkout?suffix=b35&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F01.AOG.0000249610.95885.efhttp://www.birpublications.org/servlet/linkout?suffix=b36&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1001%2Fjama.1983.03340220040030http://www.birpublications.org/servlet/linkout?suffix=b37&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2FS0002-9378(94)70090-7http://www.birpublications.org/servlet/linkout?suffix=b38&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1038%2Fbjc.1994.440http://www.birpublications.org/servlet/linkout?suffix=b38&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1038%2Fbjc.1994.440http://www.birpublications.org/servlet/linkout?suffix=b23&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0090-8258(84)90200-2http://www.birpublications.org/servlet/linkout?suffix=b24&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F00004728-200411000-00018http://www.birpublications.org/servlet/linkout?suffix=b25&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0360-3016(92)90781-Chttp://www.birpublications.org/servlet/linkout?suffix=b26&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F00000478-200011000-00001http://www.birpublications.org/servlet/linkout?suffix=b27&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1002%2Fuog.1823http://www.birpublications.org/servlet/linkout?suffix=b28&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.184.3.01840999http://www.birpublications.org/servlet/linkout?suffix=b30&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F01.gco.0000233935.51801.48http://www.birpublications.org/servlet/linkout?suffix=b33&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1006%2Fgyno.2000.6027http://www.birpublications.org/servlet/linkout?suffix=b34&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F01.AOG.0000154884.20872.c4http://www.birpublications.org/servlet/linkout?suffix=b35&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1097%2F01.AOG.0000249610.95885.efhttp://www.birpublications.org/servlet/linkout?suffix=b36&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1001%2Fjama.1983.03340220040030http://www.birpublications.org/servlet/linkout?suffix=b37&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2FS0002-9378(94)70090-7http://www.birpublications.org/servlet/linkout?suffix=b38&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1038%2Fbjc.1994.440
8/18/2019 Imaging in Ovarian Cancer
16/19
. $)CO1) study.(ynecol %ncol 887DE(*&7EF&7. Cross4ef
.
Carter H. #rimary surgery for ovarian cancer. In* , !ershenson $, c!uire B#, !ore ,
eds. (ynecologic cancer& contro#er$ie$ in management . #hiladelphia, #)* Alsevier@tdD &77. pp. E8(F78.
&
.
4ose #!, :erenstone ", +rady , Clar=e-#earson $, Olt !, 4ubin "C, et al.. "econdary
surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med &77D&*&(8F 8. Cross4ef
E
.
artine= IA, 6ehoe ". Bhen should surgical cytoreduction in advanced ovarian cancer ta=e
placeP J %ncol &77D&77*(%&7&(. Cross4ef
.
1ergote I, TropQ C!, )mant , 6ristensen !+, Ahlen T, Hohnson :, et al.. :eoadRuvantchemotherapy or primary surgery in stage IIIC or I1 ovarian cancer. N Engl J
Med &77DEGE*8EF%E. Cross4ef
%.
Billiams @@. "econdary cytoreduction of ovarianmalignancies. In* , ar=man , ?os=ins BH, eds. Cancer of the o#ary. :ew or=,
:* 4aven #ressD 88E. pp. (F&7E.
G
.
+ere= H", ?ac=er :, @agasse @$, #oth T, 4esnic= +, :ieberg 46. "econd-loo= laparotomy
in stage III epithelial ovarian cancer* clinical variables associated with disease status. %b$tet(ynecol 8(DG*&7F&.
.
"trigini ), !adducci ), $el +ravo +, erdeghini , !enaani )4. $ifferential diagnosis
of adnexal masses with transvaginal sonography, color flow imaging and pre and postmenopausal women. (ynecol %ncol 88GDG*G(F&. Cross4ef
(
.
6roon A, )ndolf A. $iagnosis and follow-up of simple ovarian cysts detected by ultrasound
in postmenopausal women. %b$tet (ynecol 88%D(%*&F. Cross4ef
8.
oyle HB, 4ochester $, "ider @, "hroc= 6, 6rause #. "onography of ovarian tumours* predictability of tumour type. AJR Am J Roentgenol 8ED*8(%F8.
%7
.
"assone ), Timor-Tritsch I, )rtner ), Besthoff C, Barren B. Transvaginal sonographic
characterisation of ovarian disease* evaluation of a new scoring system to predictmalignancy. %b$tet (ynecol 88D(*7FG.
%
.
+rown $@, $obliet #, iller ?, rates C, @aing C, $i"alvo $:, et al.. +enign and
malignant ovarian masses* selection of the most discriminating gray-scale and doppler
sonographic features. Radiology 88(D&7(*7EF7.Cross4ef
%&
.
Hohnson 4H. anagement of ovarian cancer. Clin Radiol 88ED(*%F(&. Cross4ef
%E.
Hain 6). #rospective evaluation of adnexal masses and endovaginal gray-scale and duplexand color doppler 5"* correlation with pathologic findings. Radiology 88D8*GEF
. Cross4ef
%
.
leischer )C, 4ogers B?, 4ao +6, 6epple $, Hones ?B. Transvaginal color doppler
sonography of ovarian masses with pathological correlation. 'ltra$ound %b$tet(ynecol 88D*&%. Cross4ef
%%
.
?amper 5, "heth ", )bbas , 4osenshein :, )ronson $, 6urman 4. Transvaginal color
doppler sonography of adnexal masse* differences in blood flow impedance in benign andmalignant lesions. AJR Am J Roentgenol 88EDG7*&&%F(. Cross4ef
%G
.
+rown $, rates , @aing , $i "alvio $, $oubliet #, +ensen C, et al.. Ovarian masses* can
benign and malignant lesions be differentiated with color and pulsed doppler
5"P Radiology 88D87*EEEFG. Cross4ef
http://www.birpublications.org/servlet/linkout?suffix=b40&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0090-8258(90)90042-Jhttp://www.birpublications.org/servlet/linkout?suffix=b42&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1056%2FNEJMoa041125http://www.birpublications.org/servlet/linkout?suffix=b42&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1056%2FNEJMoa041125http://www.birpublications.org/servlet/linkout?suffix=b43&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1155%2F2010%2F852028http://www.birpublications.org/servlet/linkout?suffix=b43&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1155%2F2010%2F852028http://www.birpublications.org/servlet/linkout?suffix=b44&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1056%2FNEJMoa0908806http://www.birpublications.org/servlet/linkout?suffix=b44&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1056%2FNEJMoa0908806http://www.birpublications.org/servlet/linkout?suffix=b47&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1006%2Fgyno.1996.0098http://www.birpublications.org/servlet/linkout?suffix=b48&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0029-7844(94)00366-Lhttp://www.birpublications.org/servlet/linkout?suffix=b51&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.208.1.9646799http://www.birpublications.org/servlet/linkout?suffix=b52&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2FS0009-9260(05)81076-1http://www.birpublications.org/servlet/linkout?suffix=b53&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.191.1.8134599http://www.birpublications.org/servlet/linkout?suffix=b53&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.191.1.8134599http://www.birpublications.org/servlet/linkout?suffix=b54&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1046%2Fj.1469-0705.1991.01040275.xhttp://www.birpublications.org/servlet/linkout?suffix=b55&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.160.6.8498222http://www.birpublications.org/servlet/linkout?suffix=b56&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.190.2.8284377http://www.birpublications.org/servlet/linkout?suffix=b40&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0090-8258(90)90042-Jhttp://www.birpublications.org/servlet/linkout?suffix=b42&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1056%2FNEJMoa041125http://www.birpublications.org/servlet/linkout?suffix=b43&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1155%2F2010%2F852028http://www.birpublications.org/servlet/linkout?suffix=b44&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1056%2FNEJMoa0908806http://www.birpublications.org/servlet/linkout?suffix=b47&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1006%2Fgyno.1996.0098http://www.birpublications.org/servlet/linkout?suffix=b48&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2F0029-7844(94)00366-Lhttp://www.birpublications.org/servlet/linkout?suffix=b51&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.208.1.9646799http://www.birpublications.org/servlet/linkout?suffix=b52&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2FS0009-9260(05)81076-1http://www.birpublications.org/servlet/linkout?suffix=b53&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.191.1.8134599http://www.birpublications.org/servlet/linkout?suffix=b54&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1046%2Fj.1469-0705.1991.01040275.xhttp://www.birpublications.org/servlet/linkout?suffix=b55&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.160.6.8498222http://www.birpublications.org/servlet/linkout?suffix=b56&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.190.2.8284377
8/18/2019 Imaging in Ovarian Cancer
17/19
%
.
endelson A+, +ohm-1ele . Transvaginal ultrasonography of pelvic neoplasms. Radiol
Clin N Am88&DE7*7EFE.
%(.
Hoshi , !anesan 6, unshi ?:, !anesan ", @awande ). 5ltrasound of adnexalmasses. Semin 'ltra$ound C" MR! &77(D&8*&F8. Cross4ef
%8
.
Tempany C, Jou 6?, "ilverman "!, +rown $@, 6urt )+, c:eill +H. "taging of
advanced ovarian cancer* comparison of imaging modalitiesSreport from the 4adiology$iagnostic Oncology !roup "tudy. Radiology&777D&%*GF. Cross4ef
G7
.
Hacobs I, Oram $, airban=s H, Turner H, rost C, !rudins=as H!. ) ris= of malignancy
index incorporating C) &%, ultrasound and menopausal status for the accurate pre-operative
diagnosis of ovarian cancer. r J %b$tet (ynaecol 887D8*8&&F8. Cross4ef
G
.
4oach ", ?ulse #. Ovarian Cancer. In* , ?ulse #, Carrington +, eds. MR! manual of pel#ic
cancer . @ondon, 56*Taylor and rancisD &77. pp. 8&FG.
G&.
Outwater A6, $unston CH. Imaging of the ovary and adnexal* clinical issues and applicationsof 4 imaging. Radiology 88%D8*F(. Cross4ef
GE
.
"tevens "6, ?rica= ?, "tern H@. Ovarian lesions* detection and characterisation with
gadolinium enhanced 4imaging at .%T. Radiology 88D(*(F(. Cross4ef
G.
@ow 4:, rancis I4. 4 imaging of the gastrointestinal tract with i.v. gadolinium anddiluted barium oral contrast media compared with unenhanced 4 imaging and CT. AJR Am
J Roentgenol 88DG8*7%F8. Cross4ef
G%.
@ow 4:, +arone 4, @acey C, "igeti H", )late !$, "ebrechts C#. #eritoneal tumour*4 imaging with dilute oral barium and intravenous gadolinium-compared with unenhanced
4 imaging and CT. Radiol 88D&7*%EF&7. Cross4ef
GG
.
6urt )+, Tsima=as , Tempany CC, ?amper 5, )rger #?, +ree 4@, et al.. $iagnosis
and staging of ovarian cancer* comparative values of doppler and conventional 5", CT and4 imaging correlated with surgery and histopathologic analysisSreport of the 4adiology
$iagnostic Oncology !roup. Radiology 888D&&*8F&. Cross4ef
G. amshita , Torashima , ?atana=a , , ?arada , ?igashida , Ta=ahashi , etal.. )dnexal masses* accuracy of characteriation with transvaginal 5" and pre-contrast and
post-contrast 4 imaging. Radiology88%D8*%%FG%. Cross4ef
G(
.
6in=el 6, @u , ehdiade ), #elte , ?rica= ?. Indeterminate ovarian mass on 5"*
incremental value of second imaging test for characterisationSmeta-analysis and +ayesiananalysis. Radiology &77%D&EG*(%F8. Cross4ef
G8
.
"ohaib "), ills T$, "ahdev ), Bebb H), 1antrappen #O, Hacobs IH, et al.. The role of
magnetic resonanceimaging and ultrasound in patients with adnexal masses. Clin Radiol &77%DG7*E7F(. Cross4ef
7
.
?rica= ?, Chen , Coa=ley 1, 6in=el 6, u 66, "ica !, et al.. Complex adnexal masses*
detection and characterisation with 4 imaging, multivariate
analysis. Radiology &777D&*E8FG. Cross4ef
.
#a==al 1, +alogun . Imaging of ovarian cancer. !maging &77GD(*&7F. @in=
&.
itchell $!, ?ill C, Jaloude= C. "erous carcinoma of the ovary* CT identification ofmetastatic calcified implants. Radiology 8(GD%(*G8F%&. Cross4ef
E
.
#annu ?6, +ristow 4A, ont H, ishman A6. ultidetector CT of peritoneal
carcinomatosis from ovarian cancer. Radiographic$ &77ED&E*G(F7. Cross4ef
Heong , Outwater A6, 6ang?6 . Imaging evaluation of ovarian
http://www.birpublications.org/servlet/linkout?suffix=b58&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1053%2Fj.sult.2008.01.004http://www.birpublications.org/servlet/linkout?suffix=b59&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.215.3.r00jn25761http://www.birpublications.org/servlet/linkout?suffix=b59&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.215.3.r00jn25761http://www.birpublications.org/servlet/linkout?suffix=b60&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1111%2Fj.1471-0528.1990.tb02448.xhttp://www.birpublications.org/servlet/linkout?suffix=b62&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.194.1.7997533http://www.birpublications.org/servlet/linkout?suffix=b62&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.194.1.7997533http://www.birpublications.org/servlet/linkout?suffix=b63&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.181.2.1924792http://www.birpublications.org/servlet/linkout?suffix=b63&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.181.2.1924792http://www.birpublications.org/servlet/linkout?suffix=b64&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.169.4.9308464http://www.birpublications.org/servlet/linkout?suffix=b65&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.204.2.9240546http://www.birpublications.org/servlet/linkout?suffix=b66&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.212.1.r99jl3619http://www.birpublications.org/servlet/linkout?suffix=b66&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.212.1.r99jl3619http://www.birpublications.org/servlet/linkout?suffix=b67&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.194.2.7824738http://www.birpublications.org/servlet/linkout?suffix=b67&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.194.2.7824738http://www.birpublications.org/servlet/linkout?suffix=b68&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiol.2361041618http://www.birpublications.org/servlet/linkout?suffix=b69&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2Fj.crad.2004.09.007http://www.birpublications.org/servlet/linkout?suffix=b70&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.214.1.r00ja3939http://www.birpublications.org/doi/10.1259/imaging/33821213http://www.birpublications.org/doi/10.1259/imaging/33821213http://www.birpublications.org/servlet/linkout?suffix=b72&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.158.3.3945732http://www.birpublications.org/servlet/linkout?suffix=b73&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Frg.233025105http://www.birpublications.org/servlet/linkout?suffix=b73&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Frg.233025105http://www.birpublications.org/servlet/linkout?suffix=b58&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1053%2Fj.sult.2008.01.004http://www.birpublications.org/servlet/linkout?suffix=b59&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.215.3.r00jn25761http://www.birpublications.org/servlet/linkout?suffix=b60&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1111%2Fj.1471-0528.1990.tb02448.xhttp://www.birpublications.org/servlet/linkout?suffix=b62&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.194.1.7997533http://www.birpublications.org/servlet/linkout?suffix=b63&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.181.2.1924792http://www.birpublications.org/servlet/linkout?suffix=b64&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.2214%2Fajr.169.4.9308464http://www.birpublications.org/servlet/linkout?suffix=b65&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.204.2.9240546http://www.birpublications.org/servlet/linkout?suffix=b66&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.212.1.r99jl3619http://www.birpublications.org/servlet/linkout?suffix=b67&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.194.2.7824738http://www.birpublications.org/servlet/linkout?suffix=b68&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiol.2361041618http://www.birpublications.org/servlet/linkout?suffix=b69&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2Fj.crad.2004.09.007http://www.birpublications.org/servlet/linkout?suffix=b70&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.214.1.r00ja3939http://www.birpublications.org/doi/10.1259/imaging/33821213http://www.birpublications.org/servlet/linkout?suffix=b72&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Fradiology.158.3.3945732http://www.birpublications.org/servlet/linkout?suffix=b73&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1148%2Frg.233025105
8/18/2019 Imaging in Ovarian Cancer
18/19
. masses. Radiographic$ &777D&7*%F7. Cross4ef
%
.
+uy H:, oss )), "coit C, +aot , !uinet C, #rQvot ", et al.. Apithelial tumours of
the ovary* CT findings and correlation with 5". Radiology 8((DG8*8.
G
.
Coa=ley , Choi #, !ourgoutas C, #othuri +, 1en=atranam A, Chi $, et al.. #eritoneal
metastases* detection with spiral CT in patients with ovarian
cancer. Radiology &77&D&&E*8%F8. Cross4ef
.
Hung "A, @ee H, 4ha "A, +yun ", Hung HI, ?ahn "T. CT and 4I imaging of ovarian
tumors with emphasis on differential diagnosis. Radiographic$ &77&D&&*E7%F&%. Cross4ef
(
.
6ormano , !rnroos . Computer-tomographic evaluation of gynecologic tumors. Acta
%b$tet (ynecol Scand 8(DGE*%78FG. Cross4ef
8
.
Iyer 14, @ee "I. 4I, CT and #AT
8/18/2019 Imaging in Ovarian Cancer
19/19
Radiol &778D*GF. Cross4ef
8&
.
+hosale #, Iyer 4. $iagnostic imaging in gynaecologic malignancy. Miner#a
(inecol &77(DG7*EF%.
8E
.
ura=ami , iyamoto T, @ida T, Tsu=ada ?, Batanabe , "hida , et al.. Bhole body
#AT and tumour mar=er C)&% for detection of recurrence in epithelial ovarian cancer. !nt J
(ynecol Cancer &77GDG"uppl. 388F7. Cross4ef
http://www.birpublications.org/servlet/linkout?suffix=b91&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2Fj.ejrad.2008.02.019http://www.birpublications.org/servlet/linkout?suffix=b93&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1111%2Fj.1525-1438.2006.00471.xhttp://www.birpublications.org/servlet/linkout?suffix=b91&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1016%2Fj.ejrad.2008.02.019http://www.birpublications.org/servlet/linkout?suffix=b93&dbid=16&doi=10.1259%2Fimaging.20100060&key=10.1111%2Fj.1525-1438.2006.00471.x